Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Inactivated |
Clinical data | |
Other names | VLA2001,[1] VLA2101, COVID-19 Vaccine (inactivated, adjuvanted) Valneva[2] |
Routes of administration | Intramuscular |
ATC code | |
Legal status | |
Legal status |
Part of a series on the |
COVID-19 pandemic |
---|
![]() |
|
![]() |
Valneva COVID-19 vaccine was a COVID-19 vaccine developed by French biotechnology company Valneva SE in collaboration with the American biopharmaceutical company Dynavax Technologies.[6][7][8]
In April 2022, the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) approved the vaccine, being the first in the world to do so.[3] It was approved for medical use in the European Union in June 2022.[2]
MHRA20220414
was invoked but never defined (see the help page).